246 results
8-K
EX-99.1
ACHV
Achieve Life Sciences Inc.
28 Mar 24
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
4:06pm
receptors in the brain, reducing the severity of withdrawal symptoms, and reducing the reward and satisfaction associated with nicotine products
8-K
EX-10.1
ACHV
Achieve Life Sciences Inc.
29 Feb 24
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
4:41pm
. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Upon satisfaction of the covenants … and shall not use such proceeds: (a) for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the ordinary
8-K
EX-99.1
ACHV
Achieve Life Sciences Inc.
29 Feb 24
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
4:41pm
the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed for the treatment
8-K
EX-4.1
ACHV
Achieve Life Sciences Inc.
29 Feb 24
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
4:41pm
or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
424B5
6g44kj8aoa
29 Feb 24
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
fqe w1ua9dfdo
9 Nov 23
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
4:05pm
8-K
EX-99.1
633rr
14 Aug 23
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
4:06pm
8-K
EX-99.1
rnun78i jqlp2rw7lvv5
25 May 23
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
9:06am
8-K
EX-10.1
r9q1xnx16o
25 May 23
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
9:06am
8-K
EX-99.1
6frgr
23 May 23
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
6:13am
8-K
EX-10.1
xlyqh j8rqsj32v
17 May 23
Entry into a Material Definitive Agreement
8:07am
8-K
EX-99.1
ze8jgx7
9 May 23
Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update
4:13pm
8-K
EX-99.1
8nc67
30 Mar 23
Achieve Life Sciences Announces Refresh to Board of Directors
8:08am
8-K
EX-99.1
ygvewit79cwo
18 Nov 22
Achieve Life Sciences Announces Private Placement of $18.9 Million
4:05pm